Registry connects COVID-19 trials with motivated patients

With the pharmaceutical trade pursuing COVID-19 vaccines and coverings, researchers are keen to attach with potential trial patients to enroll in myriad research. TopicWell has launched a registry of patients which have indicated curiosity in taking part in such analysis, to assist contribute to growth of preventives and cures—by the top of May, the registry included greater than 67,000 motivated potential enrollees.

TopicWell CEO Ivor Clarke informed Outsourcing-Pharma that the COVID-19 has introduced unprecedented interruptions to the pharmaceutical trade, alongside with an pressing must develop a vaccine and different options.

Motivated patients

“As clinical trials for a COVID-19 vaccine become more widely available, we know our partners across the industry will need to find trial participants quickly and efficiently​,” Clarke informed us. “As part of regular business operations, our recruiters speak with thousands of patients each day prescreening them against the eligibility criteria for multiple Phase II-IV clinical trials; we found that nearly 80% of these people also wanted to volunteer to help combat COVID-19​.”

Clarke additionally identified that accessing a sizeable record of potential trial members presents pharmaceutical firms and different stakeholders a possible shortcut to outcomes.

“The information from our COVID-19 patient registry list was developed to remove a large hurdle for our partners: access to interested patients and their medical information as they prepare to kick off widespread COVID-19 clinical research​,” Clarke stated. “By sidestepping the lengthy process of identifying participants for a clinical trial, the list can help bring about a vaccine at a faster speed, impacting the decision makers, problem solvers and general public during the pandemic.​”